Your Health, We Care
News, as an important means of information dissemination, covers a variety of fields and aspects, It is of great significance for transmitting information, establishing an image, and promoting development. Here, we will introduce in detail the three sections company news, medicine news, and research news.
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combination with BCG (Bacillus Calmette-Guérin) induction and maintenance regimen has rec···【more】
Article source: Captain MedicineRelease date: 2026-06-01Recommended: 70
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alf···【more】
Article source: Captain MedicineRelease date: 2025-12-17Recommended: 424
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination with abiraterone acetate (brand name: Akeega, Janssen Biotech, Inc.) plus predni···【more】
Article source: Captain MedicineRelease date: 2025-12-15Recommended: 392
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubicel-onlv), the first hematopoietic stem cell transplantation (HSCT) therapy for th···【more】
Article source: Captain MedicineRelease date: 2025-12-10Recommended: 406
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (Breyanzi, developed by Juno Therapeutics, a subsidiary of Bristol Myers Squibb) ···【more】
Article source: Captain MedicineRelease date: 2025-12-08Recommended: 400
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for the treatment of adult patients with r···【more】
Article source: Captain MedicineRelease date: 2025-12-04Recommended: 453
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 study showed that for patients with HER2-positive locally advanced or metastatic ···【more】
Article source: Captain MedicineRelease date: 2025-12-01Recommended: 370
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrophy (SMA), announced today its welcome for the U.S. Food and Drug Administration ···【more】
Article source: Captain MedicineRelease date: 2025-11-27Recommended: 349
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued favorable opinions, proposing an amendment to the mark···【more】
Article source: Captain MedicineRelease date: 2025-01-13Recommended: 616
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced solid tumors, although further prospective research is still required. Historica···【more】
Article source: Captain MedicineRelease date: 2025-01-06Recommended: 530
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administration (FDA) has given the green light to the first generic version of Victoza (···【more】
Article source: Captain MedicineRelease date: 2024-12-30Recommended: 594
The new indication involves the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer with tumors with EGFR exon 19 deletion or exon 21 (L858R)···【more】
Article source: Captain MedicineRelease date: 2024-12-24Recommended: 507
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：4242025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：6062024-09-07
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combinati···【more】
Recommended：702026-01-06
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：3922025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：4062025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：4002025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：4532025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3702025-01-12
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
